Celldex Therapeutics (CLDX) EBITDA (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly EBITDA of -$84.4 million for Q1 2026, down 34.58% year-over-year from -$129.1 million in Q1 2025, and up 3.12% quarter-over-quarter from -$87.2 million in Q4 2025.
Celldex Therapeutics (CLDX) EBITDA (2010 - 2026) Analysis & Trends
Celldex Therapeutics' EBITDA history runs 17 years deep, the most recent figure standing at -$84.4 million for Q1 2026.
- In Q1 2026, EBITDA fell 34.58% year-over-year to -$84.4 million; the TTM figure through Mar 2026 stood at -$309.1 million (down 42.29% YoY), while the FY2025 annual figure was -$287.4 million, down 47.31% from the prior year.
- EBITDA for Q1 2026 stood at -$84.4 million, up from -$87.2 million in the prior quarter.
- The five-year high for EBITDA was -$23.3 million in Q1 2022, with the low at -$87.2 million in Q4 2025.
- The 5-year median for EBITDA is -$46.3 million (2024), against an average of -$49.2 million.
- The sharpest annual moves came in 2022 and 2023: EBITDA slumped 170.8% in 2022, then climbed 8.77% in 2023.
- Celldex Therapeutics' EBITDA stood at -$27.9 million in 2022, then sank by 70.8% to -$47.6 million in 2023, then retreated by 17.64% to -$56.0 million in 2024, then slumped by 55.56% to -$87.2 million in 2025, then rose by 3.12% to -$84.4 million in 2026.
- Business Quant data shows CLDX's EBITDA at -$84.4 million in Q1 2026, -$87.2 million in Q4 2025, and -$73.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | -80.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -80.62 Mn |
| Mar 31, 2026 | -84.44 Mn |
| Dec 31, 2025 | -87.15 Mn |
| Sep 30, 2025 | -73.62 Mn |
| Jun 30, 2025 | -63.86 Mn |
| Mar 31, 2025 | -62.74 Mn |
| Dec 31, 2024 | -56.03 Mn |
| Sep 30, 2024 | -52.13 Mn |
| Jun 30, 2024 | -46.32 Mn |
| Mar 31, 2024 | -40.61 Mn |
| Dec 31, 2023 | -47.63 Mn |
| Sep 30, 2023 | -41.24 Mn |
| Jun 30, 2023 | -33.21 Mn |
| Mar 31, 2023 | -32.47 Mn |
| Dec 31, 2022 | -27.89 Mn |
| Sep 30, 2022 | -27.70 Mn |
| Jun 30, 2022 | -36.40 Mn |
| Mar 31, 2022 | -23.26 Mn |
| Dec 31, 2021 | -20.34 Mn |
| Sep 30, 2021 | -20.82 Mn |